JP2017529067A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529067A5 JP2017529067A5 JP2017506890A JP2017506890A JP2017529067A5 JP 2017529067 A5 JP2017529067 A5 JP 2017529067A5 JP 2017506890 A JP2017506890 A JP 2017506890A JP 2017506890 A JP2017506890 A JP 2017506890A JP 2017529067 A5 JP2017529067 A5 JP 2017529067A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding protein
- seq
- chain domain
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2014/002177 | 2014-08-07 | ||
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP15154772.6A EP2982693A1 (en) | 2014-08-07 | 2015-02-11 | CD3 binding domain |
| EP15154772.6 | 2015-02-11 | ||
| PCT/EP2015/068070 WO2016020444A1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529067A JP2017529067A (ja) | 2017-10-05 |
| JP2017529067A5 true JP2017529067A5 (https=) | 2018-09-13 |
| JP6669722B2 JP6669722B2 (ja) | 2020-03-18 |
Family
ID=52468915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506890A Active JP6669722B2 (ja) | 2014-08-07 | 2015-08-05 | Ｃｄ３結合ドメイン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066015B2 (https=) |
| EP (2) | EP2982693A1 (https=) |
| JP (1) | JP6669722B2 (https=) |
| CN (1) | CN107001468B (https=) |
| AU (1) | AU2015299039B2 (https=) |
| BR (1) | BR112017002422B1 (https=) |
| CA (1) | CA2957462C (https=) |
| DK (1) | DK3177646T3 (https=) |
| HR (1) | HRP20202024T1 (https=) |
| HU (1) | HUE051919T2 (https=) |
| LT (1) | LT3177646T (https=) |
| RU (1) | RU2742691C2 (https=) |
| SI (1) | SI3177646T1 (https=) |
| WO (1) | WO2016020444A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110627907B (zh) | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
| US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| TW201902512A (zh) | 2016-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療方法 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| JP7556687B2 (ja) | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| AU2018250641B2 (en) | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| JP7247110B2 (ja) * | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗ｃｄ３抗体 |
| US11472880B2 (en) | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| WO2019160007A1 (ja) | 2018-02-14 | 2019-08-22 | 中外製薬株式会社 | 抗原結合分子および組合せ |
| US11203646B2 (en) | 2018-03-14 | 2021-12-21 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
| BR112020020604A2 (pt) | 2018-04-11 | 2021-01-12 | Inhibrx, Inc. | Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados |
| US11603405B2 (en) * | 2018-05-24 | 2023-03-14 | Janssen Biotech, Inc. | Anti-CD3 antibodies and uses thereof |
| WO2020023553A1 (en) * | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3840841A1 (en) * | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| WO2020204305A1 (ko) * | 2019-03-29 | 2020-10-08 | 주식회사 녹십자 | 항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도 |
| CN115380047A (zh) | 2020-01-29 | 2022-11-22 | 印希比股份有限公司 | Cd28单结构域抗体及其多价和多特异性构建体 |
| TWI888487B (zh) * | 2020-02-14 | 2025-07-01 | 日商協和麒麟股份有限公司 | 與ｃｄ３結合之雙特異性抗體 |
| CN116249714A (zh) | 2020-05-27 | 2023-06-09 | 詹森生物科技公司 | 包含cd3抗原结合结构域的蛋白质及其用途 |
| KR20230079409A (ko) * | 2020-09-29 | 2023-06-07 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항-cd3 항체 및 이의 용도 |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| MX2023012699A (es) | 2021-04-30 | 2023-11-21 | Hoffmann La Roche | Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3. |
| EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
| WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| AU2022424142A1 (en) | 2021-12-31 | 2024-08-08 | Kyinno Biotechnology Co., Ltd. | Anti-gprc5d antibody and use thereof |
| WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| CN119013300A (zh) | 2022-04-13 | 2024-11-22 | 豪夫迈·罗氏有限公司 | 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024152963A1 (zh) * | 2023-01-18 | 2024-07-25 | 贝达药业股份有限公司 | 抗cd3的人源化抗体及其应用 |
| WO2025224084A1 (en) | 2024-04-22 | 2025-10-30 | Engimmune Therapeutics Ag | Proteins comprising t cell receptor constant domains |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| EP1881070B1 (en) * | 1999-03-09 | 2012-10-03 | Zymogenetics, Inc. | Human cytokine as ligand of the zalpha receptor and uses thereof |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| DK1716178T3 (da) | 2004-02-16 | 2010-09-20 | Micromet Ag | Mindre immunogene bindingsmolekyler |
| AU2008319053B2 (en) * | 2007-11-01 | 2012-04-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP2698431B1 (en) * | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
| DK2714733T3 (da) * | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| EP2938637A2 (en) * | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Multivalent binding protein compositions |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN105555804B (zh) * | 2013-08-07 | 2020-12-25 | 阿菲姆德股份有限公司 | 对EGFRvIII有特异性的抗体结合位点 |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
-
2015
- 2015-02-11 EP EP15154772.6A patent/EP2982693A1/en not_active Withdrawn
- 2015-08-05 JP JP2017506890A patent/JP6669722B2/ja active Active
- 2015-08-05 HU HUE15756850A patent/HUE051919T2/hu unknown
- 2015-08-05 RU RU2017105120A patent/RU2742691C2/ru active
- 2015-08-05 CN CN201580054757.1A patent/CN107001468B/zh active Active
- 2015-08-05 EP EP15756850.2A patent/EP3177646B1/en active Active
- 2015-08-05 WO PCT/EP2015/068070 patent/WO2016020444A1/en not_active Ceased
- 2015-08-05 LT LTEP15756850.2T patent/LT3177646T/lt unknown
- 2015-08-05 BR BR112017002422-5A patent/BR112017002422B1/pt active IP Right Grant
- 2015-08-05 SI SI201531457T patent/SI3177646T1/sl unknown
- 2015-08-05 HR HRP20202024TT patent/HRP20202024T1/hr unknown
- 2015-08-05 CA CA2957462A patent/CA2957462C/en active Active
- 2015-08-05 AU AU2015299039A patent/AU2015299039B2/en active Active
- 2015-08-05 DK DK15756850.2T patent/DK3177646T3/da active
- 2015-08-06 US US14/820,462 patent/US10066015B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529067A5 (https=) | ||
| RU2017105120A (ru) | Cd3-связывающий домен | |
| JP2016536322A5 (https=) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| FI4050034T3 (fi) | Cd3:een sitoutuvia vasta-aineita | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| JP2020517287A5 (https=) | ||
| RU2015129762A (ru) | ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| RU2019100481A (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| JP2014158485A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2020510659A5 (https=) | ||
| JP2019501883A5 (https=) | ||
| JP2018527919A5 (https=) | ||
| JP2017029157A5 (https=) | ||
| JP2019506841A5 (https=) | ||
| JP2016196468A5 (https=) | ||
| FI3328893T3 (fi) | Mesoteliinia ja cd3:a sitovia bispesifisiä vasta-ainekonstrukteja | |
| JP2018502572A5 (https=) | ||
| JP2020500510A5 (https=) |